Our Product: Tiprelestat is a game changing innovation
Tiprelestat is a pioneering anti-inflammatory and tissue protective drug being developed for the treatment of pulmonary-arterial hypertension, the prevention of serious disease progression of COVID-19 and the prevention of postoperative inflammatory complications.
Our Vision: Natural protection smart reinvented
We at tiakis develop novel and groundbreaking therapeutic solutions in indications with high unmet medical need.
Our drive is to make use of the human body’s own defense mechanisms to prevent tissue damage and inflammation driven complications.
Tiprelestat - our investigational medicinal product – is being developed to be the driver of a paradigm change as a therapeutic solution in disease areas such as prevention of postoperative inflammatory complications, treatment of pulmonary-arterial hypertension and the prevention of serious disease progression of COVID-19
Mechanism of action: Tiprelestat – the tissue protective agent
Tiprelestat is identical to the human protein elafin and a potent reversible inhibitor of human neutrophil elastase and proteinase 3. It’s able to inhibit their activity almost completely in vitro and in vivo.
Tiprelestat is associated with a significantly reduced postoperative need for intensive care in patients undergoing esophageal cancer surgery.
Tiprelestat inhibits the formation of neutrophil exosomes and neutrophil extracellular traps, inhibits NFkB and restores pathologic bone morphogenic protein signaling.
Tiprelestat reduces, in vivo, vascular smooth muscle cell proliferation and vascular occlusion and promotes alveolar formation.
Tiprelestat suppresses reperfusion injury occurring after heart transplantation, myocardial infarction, and skeletal muscle ischemia.
Tiprelestat is able to revert the pathology in pulmonary arterial hypertension and to reduce ventilator induced injury.
Tiprelestat is well tolerated and has been subjected to numerous preclinical and clinical investigations in a variety of disease areas.
In-focus medical fields Tiprelestat
Pipeline: Towards progress
tiakis has driven the complete development of Tiprelestat from the discovery of human elafin at the University of Kiel to clinical proof-of-concept and has established a global network of renowned research institutes, physicians and hospitals in Europe and the US.
These are the next steps on our development path.
All advantages at a glance: Good reasons for Tiprelestat
Tiprelestat exhibits an excellent therapeutic benefit risk profile for the use as an anti-inflammatory and tissue protective drug.
Our development programs are focused on our late-stage indication major surgery, and our early-stage indications pulmonary arterial hypertension (PAH) and COVID-19.
In major surgery for instance, we were able to significantly reduce intensive care stays. Good for patient health and more efficient, plannable intensive care bed assignment.